Recently, we further prove that MD2 could also be an attractive therapeutic target for the treatment of many non-infectious chronic inflammatory diseases, including cardiac/kidney injuries induced by hypertension 19, obesity 20, 21, and diabetes 22. The gene discussed is LY96; the disease is obesity due to melanocortin 4 receptor deficiency.